OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 114 filers reported holding OCULAR THERAPEUTIX INC in Q3 2023. The put-call ratio across all filers is 0.46 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $65,212 | -72.4% | 20,768 | -54.6% | 0.00% | -70.0% |
| Q2 2023 | $235,900 | -2.1% | 45,717 | 0.0% | 0.01% | -16.7% |
| Q1 2023 | $240,929 | -91.1% | 45,717 | -95.3% | 0.01% | -90.8% |
| Q4 2022 | $2,712,327 | -56.6% | 965,241 | -35.9% | 0.13% | -59.4% |
| Q3 2022 | $6,252,000 | +6.1% | 1,506,456 | +2.8% | 0.32% | +6.6% |
| Q2 2022 | $5,892,000 | -7.9% | 1,465,702 | +13.5% | 0.30% | +24.2% |
| Q1 2022 | $6,395,000 | -13.3% | 1,291,905 | +22.1% | 0.24% | -10.3% |
| Q4 2021 | $7,372,000 | -13.2% | 1,057,727 | +24.5% | 0.27% | -11.7% |
| Q3 2021 | $8,496,000 | -51.0% | 849,600 | -30.6% | 0.31% | -51.3% |
| Q2 2021 | $17,349,000 | -18.3% | 1,223,500 | -5.5% | 0.63% | -17.6% |
| Q1 2021 | $21,248,000 | -13.8% | 1,294,850 | +8.7% | 0.77% | -6.2% |
| Q4 2020 | $24,648,000 | – | 1,190,703 | – | 0.82% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SUMMER ROAD LLC | 3,804,788 | $15,105,000 | 43.34% |
| Versant Venture Management, LLC | 2,215,384 | $8,795,074,000 | 2.90% |
| Opaleye Management Inc. | 1,900,000 | $7,543,000 | 2.09% |
| SV Health Investors, LLC | 628,236 | $2,494,000 | 1.46% |
| Endurant Capital Management LP | 716,124 | $2,843,000 | 1.12% |
| DELTEC ASSET MANAGEMENT LLC | 824,747 | $3,274,000 | 0.72% |
| NOTTINGHAM ADVISORS, INC. | 146,946 | $583,000 | 0.08% |
| Jump Trading, LLC | 39,255 | $156,000 | 0.05% |
| Man Group plc | 1,723,456 | $6,842,000 | 0.03% |
| JGP Global Gestao de Recursos Ltda. | 13,880 | $55,000 | 0.02% |